Japan Liquid Biopsy Market (2025-2030)
The Japan Liquid Biopsy Market was valued at $122.2 Million in 2025 and projected to reach to $245 Million by 2030, representing a compound annual growth rate of 14.9%. Japan's liquid biopsy market is positioned for exceptional growth, expanding from $122.2 million in 2025 to $245.0 million by 2030, driven by demographic shifts and healthcare modernization.
Japan Liquid Biopsy Market Trends and Insights
- Japan is emerging as a key regional hub for non-invasive diagnostic innovation, driven by an aging population and increasing cancer prevalence.
- The market in Japan benefits from advanced healthcare infrastructure, strong regulatory frameworks, and significant investment in precision medicine technologies. The 14.9% compound annual growth rate in Japan outpaces the global average, reflecting heightened adoption of liquid biopsy tests across oncology and other therapeutic areas.
- Japan's healthcare system prioritizes early detection and personalized treatment approaches, creating favorable conditions for liquid biopsy expansion.
- Between 2025 and 2030, Japan is expected to consolidate its position as a leading market within Asia Pacific, supported by collaborations between domestic and international diagnostic companies..
Key Market Statistics
- CAGR (2025-2030) 14.9% CAGR
- Market Size, 2025 ~USD 122.2 Million
- Forecast, 2030 ~USD 245 Million
- Country Japan
Japan Liquid Biopsy Market Overview
Aging Population Driving Demand :
Japan's rapidly aging demographic, with over 29% of the population aged 65+, is significantly increasing cancer incidence rates and creating substantial demand for early detection solutions through liquid biopsy technologies.
Advanced Healthcare Infrastructure :
Japan's world-class healthcare system, coupled with high healthcare spending and widespread adoption of cutting-edge diagnostic technologies, provides an ideal environment for liquid biopsy market expansion and innovation.
Strong Regulatory Framework :
Japan's robust regulatory environment through the PMDA (Pharmaceuticals and Medical Devices Agency) ensures rigorous approval processes, building trust in liquid biopsy diagnostics and accelerating market legitimacy.
Rapid Market Expansion :
With a 14.9% CAGR from 2025 to 2030, Japan's liquid biopsy market is growing faster than the global average of 11.8%, reflecting strong regional adoption and investment in non-invasive diagnostic innovation.
Japan Liquid Biopsy Market Dynamics
- The aging population combined with rising cancer prevalence creates sustained demand for early detection solutions.
- Japan's advanced healthcare infrastructure and stringent regulatory standards ensure high-quality product adoption and market credibility. Key growth catalysts include increased healthcare spending, growing physician awareness of liquid biopsy benefits, and strategic partnerships between domestic and international diagnostic companies.
- Investment in research and development, coupled with government initiatives supporting precision medicine, will further accelerate market penetration across oncology, cardiovascular, and other therapeutic areas throughout the forecast period..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Qiagen N.V.
- Agilent Technologies, Inc.
- Danaher Corporation
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- Japan's liquid biopsy market is valued at $122.2 million in 2025 and will double to $245.0 million by 2030, growing at a 14.9% CAGR.
- Japan's growth rate significantly exceeds the global average of 11.8%, positioning the country as a high-growth market within Asia Pacific.
- Japan's aging demographic and elevated cancer incidence drive demand for non-invasive, early-detection diagnostic solutions.
- Japan's advanced healthcare infrastructure and regulatory environment support rapid adoption and commercialization of liquid biopsy technologies.
Liquid Biopsy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CIRCULATING TUMOR DNA (Circulating Biomarker Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 11.8% from 2025 to 2030 |
| Largest Segment | BLOOD (Sample Type) |
| Market Size Base Year (Billions) | ~USD 4.04 (2025) |
| Revenue Forecast (Billions) | ~USD 7.05 (2030) |
| Segments Covered | Product & Service, Circulating Biomarker Type, Technology, Application, Type, Clinical Application, Sample Type, End User |
Japan Liquid Biopsy Market Report Segmentation
8 segment dimensions are covered across the global market.
By Product & Service
- Assay Kits
- Instruments
- Services
By Circulating Biomarker Type
- Cell-Free Dna
- Circulating Tumor Cells
- Circulating Tumor Dna
- Extracellular Vesicles
- Other Circulating Biomarkers
By Technology
- Multi-Gene Parallel Analysis Using Ngs
- Single-Gene Analysis Using Pcr Microarrays
By Application
- Cancer Applications
- Non-Cancer Applications
By Type
- Breast Cancer
- Colorectal Cancer
- Infectious Disease Testing
- Lung Cancer
- Melanoma
- Non-Invasive Prenatal Testing
- Organ Transplantation
- Other Cancers
- Prostate Cancer
By Clinical Application
- Early Cancer Screening
- Recurrence Monitoring
- Therapy Selection
- Treatment Monitoring
By Sample Type
- Blood
- Other Sample Types
By End User
- Academic & Research Centers
- Hospitals & Physician Laboratories
- Hospitals & Physicians Laboratories
- Other End Users
- Reference Laboratories
Target Audience
- In Vitro Diagnostics (IVD) Manufacturers : Require Japan-specific market data to develop localized liquid biopsy products, navigate regulatory requirements, and establish distribution partnerships within Japan's premium healthcare market.
- Pharmaceutical & Biotech Companies : Need detailed market insights to identify companion diagnostic opportunities, plan clinical trial strategies, and align product development with Japan's precision medicine initiatives and reimbursement landscape.
- Healthcare Investment Firms : Seek validated market sizing and growth projections for Japan to evaluate investment opportunities, assess portfolio companies' regional expansion potential, and identify acquisition targets in the liquid biopsy space.
- Hospital & Diagnostic Laboratory Networks : Require market intelligence to make informed procurement decisions, evaluate technology adoption ROI, and plan service expansion strategies aligned with Japan's aging population healthcare needs.
- Government & Healthcare Policy Makers : Need comprehensive market analysis to inform precision medicine policy development, healthcare budget allocation, and regulatory framework updates supporting liquid biopsy innovation in Japan.
Key Companies in the Japan Liquid Biopsy Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SANOFI | France | Public Company | Vaccines (pediatric, hexavalent, travel and epidemic),Immunology & Inflammation,Rare Diseases & Neurology, |
| CONMED CORPORATION | United States | Public Company | Orthopedic sports medicine and power tools (BioBrace, Y-Knot, Hall, related disposables),General surgery and minimally invasive platforms (AirSeal, Buffalo Filter, endomechanical, electrosurgery),Endoscopic technologies and patient monitoring (GI therapeutics, ECG/EEG, defibrillation pads), |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, markers, localization, treatment),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa ProVu, CoolSeal), |
| UNITED IMAGING HEALTHCARE CO., LTD. | China | Public Company | Magnetic Resonance Imaging,Computed Tomography,Molecular Imaging (PET/CT, SPECT), |
| NATERA, INC. | United States | Public Company | Oncology MRD and CGP (Signatera, Latitude, Altera, Empower oncology use),Women’s health (Panorama, Horizon, Fetal Focus, Vistara, Anora),Transplant and nephrology (Prospera, Renasight), |
| GUARDANT HEALTH | United States | Public Company | Guardant360 liquid portfolio (CDx and Guardant360 Liquid),Guardant Reveal and minimal residual disease testing,Guardant360 Tissue and tissue-based profiling, |
| MYRIAD GENETICS, INC. | United States | Public Company | Hereditary and Companion Diagnostics (MyRisk, BRACAnalysis CDx, MyChoice CDx),Oncology Prognostics and Tumor Profiling (Prolaris, EndoPredict, Precise Tumor),Women’s Health and Prenatal (Prequel, Foresight, SneakPeek, FirstGene), |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Arrays and genotyping products, |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual and reproductive health assays, |
| EXACT SCIENCES CORPORATION | United States | Private Company | Cologuard and Cologuard Plus,Oncotype DX breast and colon tests,Hereditary and risk assessment tests (Riskguard, Cancerguard, Genetic Testing), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| GRAIL, INC. | United States | Public Company | Galleri multi-cancer early detection screening,Diagnostic aid for suspected cancer,Precision oncology and MRD/monitoring (RUO methylation platform), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Life Science segment,Clinical Diagnostics segment, |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation analyzers and reagents,Urinalysis, blood gas/electrolyte, and related analyzers, |
| MDXHEALTH | Belgium | Public Company | Confirm mdx (prostate cancer tissue test),ExoD (non-invasive urine prostate cancer test),Genomic Prostate Score collaboration, |
| PERSONALIS, INC. | United States | Public Company | Pharma and biopharma research services (ImmunoID NeXT, exome/transcriptome projects),MRD and clinical liquid biopsy (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling and Dx (NeXT Dx and related tests), |
SANOFI
Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees, operating as a public company in the healthcare and drug development sector.
CONMED CORPORATION
CONMED Corporation is a U.S.-based public company founded in 1970 with 3,900 employees that manufactures and distributes medical devices and equipment.
HOLOGIC, INC.
Hologic, Inc. is a private U.S. company founded in 1985 with 7,070 employees focused on diagnostic and surgical medical devices.
UNITED IMAGING HEALTHCARE CO., LTD.
United Imaging Healthcare Co., Ltd. is a Chinese public company founded in 2011 with 8,703 employees specializing in medical imaging equipment and solutions.
NATERA, INC.
Natera, Inc. is a U.S. public company founded in 2003 with 6,138 employees providing genetic testing and cell-free DNA analysis services.
GUARDANT HEALTH
Guardant Health is a U.S. public company founded in 2011 with 2,498 employees focused on liquid biopsy and genomic testing for cancer detection.
MYRIAD GENETICS, INC.
Myriad Genetics, Inc. is a U.S. public company founded in 1991 with 2,700 employees specializing in genetic testing and personalized medicine.
ILLUMINA, INC.
Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees that develops and manufactures DNA sequencing and genetic analysis systems.
QIAGEN N.V.
QIAGEN N.V. is a Dutch public company founded in 1984 with 5,500 employees providing molecular diagnostics and life sciences research tools.
EXACT SCIENCES CORPORATION
Exact Sciences Corporation is a U.S. private company founded in 1995 with 7,150 employees specializing in molecular diagnostics and cancer screening.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a U.S. public company founded in 1956 with 125,000 employees providing laboratory equipment, reagents, and analytical services.
GRAIL, INC.
GRAIL, Inc. is a U.S. public company founded in 2015 with 910 employees focused on early cancer detection through blood-based genomic testing.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a U.S. public company founded in 1952 with 7,450 employees manufacturing clinical diagnostics and life science research products.
SYSMEX CORPORATION
Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees specializing in in vitro diagnostics and hematology analyzers.
MDXHEALTH
MDxHealth is a Belgian public company founded in 2003 with 364 employees providing molecular diagnostics and epigenetic testing services.
PERSONALIS, INC.
Personalis, Inc. is a U.S. public company founded in 2011 with 260 employees offering whole genome sequencing and cancer genomics analysis.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation ($122.2M in 2025) and verified growth projections (14.9% CAGR) specific to Japan, enabling accurate financial forecasting and investment decision-making for regional expansion strategies.
- Competitive Landscape Intelligence : Understand Japan-specific market dynamics, key players, and competitive positioning within the region's advanced healthcare ecosystem to identify partnership opportunities and market entry strategies.
- Demographic & Clinical Insights : Access detailed analysis of Japan's aging population impact on cancer prevalence and diagnostic demand, providing evidence-based rationale for product development and market penetration planning.
- Regulatory & Reimbursement Guidance : Gain comprehensive understanding of Japan's PMDA approval pathways, reimbursement mechanisms, and healthcare policies critical for successful product launches and market commercialization.
- Strategic Growth Opportunities : Identify high-potential segments, emerging applications, and investment hotspots within Japan's liquid biopsy market to prioritize resources and maximize ROI in this high-growth regional market.
Frequently asked questions
What is the current size of Japan's liquid biopsy market?
Japan's liquid biopsy market is estimated at $122.2 million in 2025 and is projected to reach $245.0 million by 2030.
What is the growth rate of Japan's liquid biopsy market?
Japan's liquid biopsy market is growing at a compound annual growth rate (CAGR) of 14.9% from 2025 to 2030.
Why is Japan's liquid biopsy market growing faster than the global average?
Japan's 14.9% CAGR exceeds the global 11.8% average due to an aging population, high cancer prevalence, advanced healthcare infrastructure, and strong adoption of precision medicine.
What factors are driving liquid biopsy adoption in Japan?
Key drivers include Japan's aging demographic, rising cancer incidence, emphasis on early detection, robust healthcare system, and collaborations between domestic and international diagnostic companies.
How does Japan's liquid biopsy market compare to other Asia Pacific countries?
Japan is positioned as a leading market within Asia Pacific, supported by its advanced healthcare infrastructure, regulatory frameworks, and higher-than-average growth rate of 14.9%.
RESEARCH METHODOLOGY
The study involved estimating activities to determine the current size of the liquid biopsy market. Exhaustive secondary research was done to collect information on the liquid biopsy industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the liquid biopsy market.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| QIAGEN | Sales Manager |
| F. Hoffmann-La Roche Ltd. | Sales Executive |
Market Size Estimation
Liquid biopsy is a non-invasive method for diagnosing and monitoring diseases. Blood or other body fluids are collected to analyze cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or circulating tumor cells (CTCs).
Data Triangulation
After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand & supply sides.
Market Definition
Both top-down and bottom-up approaches were used to estimate and validate the liquid biopsy market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- Primary and secondary research have determined the revenues of leading players operating in the liquid biopsy market.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Stakeholders
- Manufacturers & Distributors of Liquid Biopsy Products
- Hospitals & Diagnostic Centers
- Reference Laboratories
- R&D Companies
- Research Laboratories and Academic Institutes
- Liquid Biopsy Service Providers
- Government Associations
- Venture Capitalists & Investors
Report Objectives
- To define, describe, segment, and forecast the liquid biopsy market, by product & service, circulating biomarker type, technology, application, clinical application, sample type, end user, and region
- To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and challenges)
- To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as acquisitions, collaborations, partnerships, agreements, and product launches & approvals in the liquid biopsy market
- To benchmark players within the liquid biopsy market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
Get the Full Liquid Biopsy Market Report
Full forecast, segment splits, and company analysis for all Liquid Biopsy Market.
- US Liquid Biopsy Market
- Canada Liquid Biopsy Market
- Germany Liquid Biopsy Market
- UK Liquid Biopsy Market
- France Liquid Biopsy Market
- Italy Liquid Biopsy Market
- Spain Liquid Biopsy Market
- China Liquid Biopsy Market
- India Liquid Biopsy Market
- Brazil Liquid Biopsy Market
- Mexico Liquid Biopsy Market
- Rest Of Europe Liquid Biopsy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report